Discover open access scientific publications

A Phase I, First-In-Human, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma